Good MorningInvestor confidence was rattled on Tuesday when word of not one but two trials of COVID-19 vaccines was halted due to “adverse” events. The news triggered an early morning sell-off that had the major indices down about -0.50% when the opening bell sounded. While concerning, the news was largely shrugged off in favor of earnings from JP Morgan Chase and Citigroup. The nation’s two largest consumer banks reported better than expected results that foreshadow what could be a market-moving earnings season.
Revenue at both JP Morgan and Citigroup fell on a YOY period but came in above the consensus estimates. The most noteworthy detail in either report is that reserve-builds for credit losses were less than expected. In light of the current conditions, the slowdown in reserve-build was taken as a vote of confidence in the economic recovery. If the rest of the financial sector reports in like fashion a new all-time high is in store for the S&P 500.
Featured: Copy-Paste JPMorgan's 99.52% Winning Trades (True Market Insiders) 
|
Stocks | | | A Trend Is Unfolding Before Our Very Eyes
It’s not often you can watch a trend as this unfold before your very eyes. It has been, in fact, over two years since the last time we’ve seen such a trend. What am I talking about? The fact that the analyst’s estimates are too low and upw... Read the Full Story |
|
From Our Partners2020 has been one of the most bizarre on record.
However, even with geopolitical issues, a never-ending pandemic, wildfires, earthquakes, higher unemployment, and fears of economic decay and elections, markets have pushed higher. Believing the market rally has only just begun, here are three of the top stocks that should easily outperform the major indices in the fourth quarter. | | Download Free Report Here |
|
Markets | | |
Many of the stocks that have the best long-term growth prospects are usually companies that are benefitting from secular growth trends and disrupting an entire industry. For example, we’ve seen strong performance in the market this year from companies that are at the forefront of e-commerce.... Read the Full Story |
|
Markets | | |
Sometimes a company issues positive news and its stock price inexplicably goes down. Investors that take advantage of these situations can come out ahead when the market catches up with reality.
Last week GenMark Diagnostics (NASDAQ:GNMK) provided better than expected revenue guidance and announc... Read the Full Story |
|
From Our PartnersLooking to make consistent income as a trader? Here's a simple system we've used over the last 4 years to win 93.7% of our trades. The Ultimate Income System works so well because we're not chasing home runs -- just small repeatable wins. These wins compound quickly though and can potentially become a full-time source of income, just as it has for so many others. | | CLICK HERE for instant access. |
|
Markets | | | JPMorgan Chase & Co Is A Buy After Reporting Q3 Result
After reviewing the JPMorgan Chase & Co (NYSE:JPM) calendar Q3 earnings report and looking at the chart I cannot believe this stock is still trading at such a low valuation. Trading at only 17X this year’s consensus and 12X next i... Read the Full Story |
|
Markets | | |
A Golden-Age For Fastenal?
I’ve heard (read I should say) that current conditions are a “golden age” for homebuilders. Pent-up demand, low inventory, streamlined businesses, and low-interest rates are combining in a way that means sustained, healthy business for the home builder... Read the Full Story |
|
|
The Early Bird Stock Of The Day CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California. | | View Today's Stock Pick |
|
